ViroPharma Introduces New Reconstitution System Using West’s Mix2Vial

The device and accompanying training materials will be widely available in the coming weeks.

Cinryze (C1 Esterase Inhibitor [Human]) was approved by FDA in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults.

 

"Since the launch of Cinryze, patients with HAE who are managed prophylactically with Cinryze - whether they have been trained by their healthcare provider to utilize our unique self administration option or have their physician administer their doses - have been empowered to take control of their lives," commented Daniel Soland, ViroPharma's chief operating officer.

 

"Among our goals since the launch of Cinryze is that of continuously improving the entire Cinryze experience for our patients and physicians, and we have listened closely to their feedback. We believe that the use of the Mix2Vial in combination with Cinryze offers patients, care givers and physicians a needle-less system to encourage independence and simplify the reconstitution process."

 

"Convenience and simplicity are of the utmost importance for patients and health care providers; our reconstitution system addresses both of these for Cinryze." said Fran DeGrazio, vice president, marketing and strategic business development, West (Lionville, PA).

"We are pleased that ViroPharma has chosen Mix2Vial for reconstituting Cinryze."

 

A highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product, Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.